FDA approves Teva asthma treatment

Israel’s Teva has received FDA approval for ProAir RespiClick – the first and only breath-actuated, dry-powder rescue inhaler to be approved by the FDA for the treatment of acute asthma symptoms. ProAir RespiClick eliminates the need for hand-breath coordination during inhalation.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *